← All market reports

India Healthcare Market Research Reports 2026

Regulatory focus: CDSCO

India's USD 265 billion healthcare market is anchored by the world's largest generic pharmaceutical manufacturing base—producing approximately 20% of global generics by volume and supplying 60+ countries. Rapid biosimilar manufacturing scale-up (insulin, trastuzumab, adalimumab, rituximab produced locally) anchors India as the global biosimilar cost reference. BioNixus monitors India-GCC pharmaceutical export corridors and supports Indian exporters entering GCC markets.

For cross-country benchmarking, use the market reports hub and compare therapy-specific dynamics through the oncology therapy hub.